XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) director and CEO Hugh Rogers was a featured guest on two different video interviews. In both interviews, Rogers shared key information and updates about XPhyto, a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. During his InvestorIntel interview with host Peter Clausi, Rogers mentioned that the company had recently received European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system called Covid-ID Lab, which is now registered within the European Union as a commercial in vitro diagnostic (“CE-IVD”) test. During the interview, Rogers noted that the company had gone from concept to commercial approval in less than 12 months, which is “unheard of in the biotech world.” Covid-Lab provides testing results within 25 minute of obtaining a sample, combining the speed of a rapid screening test with the accuracy of a PCR diagnostic. In an interview with Agoracom, Rogers explained how the company was advancing a number of programs simultaneously through three divisions to develop science-driven solutions solving health issues in the infectious disease screening market and how they are administered. Specifically, Rogers noted the company is working on psychedelic compounds to treat multiple mental health issues, as well as a variety of products focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. “XPhyto is a technology life science accelerator. We are advancing a number of different programs,” said XPhyto director and CEO Seth Rogers during the interview. “And first and foremost right now, taking our rapid point-of-care PCR test to markets. So we are approved in Europe for sales, and we have news coming soon in terms of distribution and partnerships and pilot products. But as you just mentioned, we have announced a shipment of 2,000 units to Israel, and that’s for the purpose of regulatory approval in Israel, looking to expand beyond Europe. So we do have a strong footprint in Germany — obviously Germany, Switzerland, Austria — the German-speaking countries would be a natural, as well as some of the larger markets, Italy, Spain, the UK in Europe. But certainly Israel, being a leader in the management and fight against COVID-19 on the testing front, on the vaccine front, it was a natural for us, being so close to Europe, to look to that market as the next step.”
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.